Next Article in Journal
Infant Feeding Pattern Clusters Are Associated with Childhood Health Outcomes
Next Article in Special Issue
Antihypertensive and Vasorelaxant Effects of Citric Acid and Lemon Juice in Spontaneously Hypertensive Rats: In Vivo and Ex Vivo Studies
Previous Article in Journal
Defining NAD(P)(H) Catabolism
Previous Article in Special Issue
Abalone Viscera Fermented with Aspergillus oryzae 001 Prevents Pressure Elevation by Inhibiting Angiotensin Converting Enzyme
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 15
Issue 13
10.3390/nu15133060
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Systematic Review

Coffee Consumption and Risk of Hypertension in Adults: Systematic Review and Meta-Analysis

by
Fahimeh Haghighatdoost
1,
Parisa Hajihashemi
2,
Amanda Maria de Sousa Romeiro
3,
Noushin Mohammadifard
4,*,
Nizal Sarrafzadegan
1,5,
Cesar de Oliveira
6,* and
Erika Aparecida Silveira
3
1
Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan 8158388994, Iran
2
Isfahan Gastroenterology and Hepatology Research Center, Isfahan University of Medical Sciences, Isfahan 8158388994, Iran
3
Postgraduate Program in Health Sciences, Faculty of Medicine, Federal University of Goiás, Goiânia 74605-050, Brazil
4
Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan 8158388994, Iran
5
School of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z3, Canada
6
Department of Epidemiology & Public Health, Institute of Epidemiology & Health Care, University College London, London WC1E 6BT, UK
*
Authors to whom correspondence should be addressed.
Nutrients 2023, 15(13), 3060; https://doi.org/10.3390/nu15133060
Submission received: 6 June 2023 / Revised: 30 June 2023 / Accepted: 4 July 2023 / Published: 7 July 2023
(This article belongs to the Special Issue Functional Foods and Hypertension)
Browse Figures
Versions Notes

Abstract

:
Objectives: The association between coffee intake and hypertension (HTN) risk is controversial. Therefore, this systematic review and meta-analysis aimed at summarizing the current evidence on the association of coffee with hypertension risk in observational studies. Methods: PubMed/Medline and Web of Science were searched for observational studies up to February 2023. Observational studies which assessed the risk of HTN in the highest category of coffee consumption in comparison with the lowest intake were included in the current meta-analysis (registration number: CRD42022371494). The pooled effect of coffee on HTN was evaluated using a random-effects model. Results: Twenty-five studies i.e., thirteen cross-sectional studies and twelve cohorts were identified to be eligible. Combining 13 extracted effect sizes from cohort studies showed that higher coffee consumption was associated with 7% reduction in the risk of HTN (95% CI: 0.88, 0.97; I2: 22.3%), whereas combining 16 effect sizes from cross-sectional studies illustrated a greater reduction in HTN risk (RR = 0.79, 95% CI: 0.72, 0.87; I2 = 63.2%). These results varied by studies characteristics, such as the region of study, participants’ sex, study quality, and sample size. Conclusions: An inverse association was found between coffee consumption and hypertension risk in both cross-sectional and cohort studies. However, this association was dependent on studies characteristics. Further studies considering such factors are required to confirm the results of this study.

1. Introduction

Hypertension is directly associated with the risk of cardiovascular diseases [1]. The number of people aged 30 to 79 years with hypertension has increased from 648 million in 1990 to more than 1.2 billion people in 2019 [2], making it a serious public health concern, especially in low and middle-income countries [3]. Additionally, evidence suggests that high-quality diets are responsible for a 22% decline in the risk of cardiovascular disease [3,4], while the consumption of red and processed meats, high sodium intake, low potassium intake, obesity, alcohol consumption, as well as sugar-sweetened beverages are associated with an increase in the risk of hypertension [1,5].
Coffee is a beverage consumed daily by a large part of the world’s population [6]. Therefore, the effects of caffeine present in coffee have been studied in recent decades through several observational studies and clinical trials [7]. Caffeine can stimulate the production of adrenaline, which in turn has several effects on the cardiovascular system, such as increased blood pressure, endothelial dysfunction, inflammation, and decreased sensitivity to insulin, which may be associated with the risk of cardiovascular diseases [8].
Previous reviews have indicated that in healthy people, habitual coffee consumption is not associated with an increased risk of hypertension [9,10,11,12], especially when the amount of coffee consumed was greater than 3 cups per day compared with 1 cup per day [13]. Reviews of prospective cohort studies demonstrated that consumption of 1–3 cups of coffee per day may increase the risk of hypertension [14,15]. However, the results from these studies are controversial, due to variations in types of coffee and their composition, lifestyle, and study duration [14,15].
At present, there is not enough scientific evidence to confirm that consumption of coffee can act in the management of hypertension [16], especially in different populations from different regions of the world, such as America, Europe, and Asia. Given these disagreements in the existing literature, this is an updated systematic review and meta-analysis that included new published studies on the relationship between coffee and HTN risk aimed to summarizing the current evidence and exploring the potential sources of heterogeneity.

2. Methods

Search Strategy and Study Selection: This meta-analysis was designed, analyzed, and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. A systematic search of the available publications was performed using the MEDLINE and Web of Science from inception (1952) to February 2023. Without any restriction on publication date and language, a search strategy applying the key terms of “(coffee OR caffeine) AND (hypertension OR “blood pressure”)” was conducted. No restriction was placed on the article language and publication date. A manual search of recent reviews and relevant original articles was performed for additional relevant studies. The study protocol was registered on the International Prospective Register of Systematic Reviews, PROSPERO (registration number: CRD42022371494).
Study selection: Two independent reviewers (FH and PH) screened titles and abstracts for eligible articles. Disagreements were resolved by discussion with C.d.O. and E.S. Then, based on the full text of identified articles, their eligibility for inclusion was assessed according to our inclusion and exclusion criteria. Studies were included if they met the following criteria: (1) original studies on adult population (aged 18 or older), (2) an observational design (prospective cohort, case-control, or cross-sectional), (3) reporting the relative risk (RR) or hazard ratio (HR) or odds ratio (OR) with 95% confidence interval (CI), and (4) assessment of hypertension or elevated blood pressure in subjects with the highest vs. the lowest intake of coffee, irrespective of coffee types and their caffeine content. Studies were excluded if they were not original research or were in vitro or animal model, conducted on adolescents or children, examined gestational or ambulatory or coffee post injection blood pressure or hypertension risk, reported blood pressure mean, assessed blood pressure control over the time, and examined HTN risk for coffee polyphenols. Disagreements were resolved through discussion until agreement was reached.
Data extraction and quality assessment: Using a pre-designed extraction form, two independent reviewers (PH and AM) extracted the following information: the author’s first name, country, year, study design, mean age or age range of participants, sample size, follow-up duration for longitudinal studies, instruments used to assess coffee intakes, the method and cut-off point used to HTN diagnosis, main findings (effect and 95% CI), and adjusted confounders. If the results of studies were reported in various groups, the information of all groups was extracted.
The quality of included studies in our meta-analysis was assessed using the New Castel Ottawa Scale (NOS) designed for observational studies. In general, this scale consisted of 3 main domains (selection, comparability, and outcome) and 8 questions in total for cohort studies. The minimum score for each domain is zero, while the maximum score varies between domains. The highest scores for participants’ selection, participants’ comparability, and assessment of outcome/exposure domains are 4, 2, and 3, respectively. The overall score ranges from zero to nine. In the adapted version for cross-sectional studies, consisting of 7 questions, the maximum score is 10. In the present study, the quality scores of ≥7 was considered methodologically high, and those with the score of 6 or fewer were considered low methodological quality [17,18].

Statistical Analysis

Hypertension risk was reported either as relative risk (RR) or odds ratio (OR). Due to the high prevalence of HTN (32% in women and 34% in men) [2], ORs were converted into RRs [19]. To combine effect sizes, a random-effects model on the basis inverse-variance method, which incorporate between-study heterogeneity [20,21] was used. Potential between-studies heterogeneity was estimated using I2 values. Heterogeneity was considered substantial when I2 values were greater than 50% [21]. Heterogeneity sources were examined using sub-group analysis based on participants’ sex, study design, geographical region of studies, participants age (< vs. >50 years), sample size (< vs. >8000 in cohort studies and < vs. >3000 in cross-sectional studies), hypertension stage (stage I and II: SBP ≥ 130 mmHg and/or DBP ≥ 80 or 85 mmHg, and only stage II: SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg) [22], study quality score (≤7 vs. >7) [23], and follow-up duration for cohort studies.
Publication bias was tested using visual inspection of a funnel plot, Egger’s test, and Begg’s tests [24,25]. Sensitivity analysis was performed to determine to which extent each individual study influences the pooled effect. All analyses were performed using the Stata 11.0 software. p values < 0.05 were regarded as significant.

3. Results

3.1. Search Results

The flowchart of study selection process is illustrated in Figure 1. Our search strategy identified 2039 articles. After removal of duplicate articles (n = 128), 1911 articles were screened for their titles and abstracts, of which 84 articles remained for further evaluation based on their full texts. Finally, 25 articles, published between 2002 and 2023, met our inclusion criteria and were included in the present meta-analysis [26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50]. Four of the twenty-five eligible articles were considered two separate studies or populations since they either consisted of two separate cohorts [45], or reported the results separately for men and women [48,49] or based on genes variants [40].

3.2. Characteristics of Studies Included in the Meta-Analysis

Table 1 and Table 2 show general characteristics of included studies in the current review. A total of 463,973 participants (321,978 from 12 cohort studies and 141,995 from 13 cross-sectional studies) were included in the meta-analysis. Overall, 11 studies were conducted in Europe [26,28,30,31,33,34,37,38,40,41,44], 9 studies in Asia [29,32,35,36,39,42,47,48,49], and 5 studies in the United States [27,43,45,46,50]. Twenty studies did not distinguish between sexes [26,27,28,29,31,32,33,34,35,36,37,38,39,41,42,43,44,47,48,49], two studies were conducted on men only [40,46], and three studies on women only [30,45,50]. Most studies evaluated the association between coffee and HTN risk, except for one which examined the associations for total antioxidants capacity of coffee [30]. One study assessed beverage consumption pattern identified by factor loading. This study was included since the pattern characterized by high consumption of unsweetened coffee and low consumption of sweetened coffee [35]. The evaluation of coffee consumption was quite heterogeneous among the included studies, with most of them classifying high coffee consumption above or equal to three cups a day [26,27,29,36,41,47], and low consumption was considered non-consumption or less than once a day or week. The volume of coffee per cup was evaluated in 8 studies [27,28,31,36,38,43,44,50], ranging from 50 to 237 mL. All studies were conducted on adults. A total of 8 studies determined blood pressure using the cut-off point of ≥130 and ≥80/85 mmHg for systolic and diastolic blood pressures [33,34,35,38,39,47,48,49], respectively, while others used the cut-off points of ≥140 and ≥90 mmHg, or taking anti-hypertension medicines of physician diagnosis. The majority of reported results suggested a null association between coffee and HTN risk (n = 18) [27,30,32,35,36,37,39,40,42,43,44,45,46,47,48,49,50], nine studies an inverse association [26,28,29,31,34,38,41,45,49], and one study suggested a positive direct link [33].

3.3. Results of Meta-Analysis

3.3.1. Cohort Studies

The pooled results of the meta-analysis revealed that individuals with the highest coffee consumption in comparison with the lowest intake had 7% lower risk for HTN (RR = 0.93, 95% CI: 0.88, 0.97; I2: 22.3%) (Figure 2). All selected cohort studies evaluated coffee consumption through a specific questionnaire. Findings from the sensitivity analysis demonstrated no change in the significance of the findings by excluding an individual study at the time. Despite a small asymmetry in the funnel plot, the Egger test (p = 0.449) and Begg test (p = 0.714) revealed no evidence of publication bias (Supplementary Figure S1).
When studies were stratified based on the geographical region of the study, higher consumption of coffee compared with the lowest was associated with lower risk of HTN in studies which were conducted in the United States (RR = 0.92, 95% CI: 0.87, 0.97; I2 = 0.7%). However, it was not associated in Europe (RR = 0.97, 95% CI: 0.83, 1.13; I2 = 60.5%) and Asia (RR = 0.94, 95% CI: 0.83, 1.07; I2 = 25.0%). The results of subgroup analysis demonstrated an inverse association in the subgroups of studies with a follow-up duration of at least 10 years (RR = 0.91, 95% CI: 0.84, 0.99), sample size less than median (RR = 0.89, 95% CI: 0.81, 0.99) and cases more than median (RR = 0.93, 95% CI: 0.89, 0.97), and those which were low quality (RR = 0.88, 95% CI: 0.83, 0.94) or conducted in females only (RR = 0.93, 95% CI: 0.88, 0.98), while in the counterpart groups a null association was found. Subgroup analysis based on age showed similar results in both groups (Table 3).

3.3.2. Cross-Sectional Studies

In cross-sectional studies, compared with the lowest amount of coffee consumption, the highest amount was associated with lower risk of HTN (OR = 0.79, 95% CI: 0.72, 0.87). Heterogeneity was considerably high between studies (I2: 63.2%) (Figure 3). Findings from the sensitivity analysis demonstrated no change in the significance of the findings by excluding an individual study at the time. No evidence of publication bias was observed (p for the Egger test = 0.198 and for the Begg test = 0.753).
Subgroup analysis based on various variables did not change the association and could not eliminate the heterogeneity except for the subgroup of women (OR = 0.88, 95% CI: 0.75, 1.02; I2 = 0.0%), studies with smaller sample size (OR = 0.84, 95% CI: 0.67, 1.04; I2 = 47.3), and those which defined HTN using the cut-off point of 130/85 mmHg (OR = 0.88, 95% CI: 0.73, 1.06; I2 = 75.2%) (Table 3).

4. Discussion

The results of the present meta-analysis suggest, overall, a slight reduction in the risk of HTN following coffee consumption. This association was observed in both cohort and cross-sectional studies, and was much stronger in cross-sectional studies. However, this association was influenced by various factors in cohort and cross-sectional studies, such as geographical region, sex, sample size, and study quality.
There are several meta-analyses evaluating the relationship between coffee and HTN risk [12,51,52]. In the most recent meta-analysis, published in November 2022, 12 prospective cohort studies were included, and a null association was found [53]. However, this study has some methodological limitations. First, they included two studies which were conducted on hypertensive individuals. Second, they did not convert OR into RR in two studies despite the high prevalence of HTN. Third, the authors failed to include two relevant studies. In addition, another earlier meta-analysis on four prospective cohort studies conducted on general population [12] revealed a null association for habitual coffee consumption and HTN. However, we identified 6 further studies published after 2017 which were not included in their meta-analysis [27,30,31,32,36,47].
Overall, this meta-analysis suggested an inverse association between coffee consumption and HTN risk in both cross-sectional and cohort studies with a small heterogeneity in prospective studies. There is a large discrepancy between studies with regard to the association of coffee and HTN risk. While some studies suggested a favorable effect [26,28,29,31], others have reported a null or an adverse association [27,37,39,40]. The plausible mechanisms underpinning the inverse association between coffee and HTN risk might be attributable to high levels of antihypertensive nutrients (i.e., vitamin E, niacin, potassium and magnesium) and polyphenols in coffee [54]. These factors can modulate blood pressure through their antioxidant and anti-inflammatory properties, and effect on nitric oxide synthesis, lipid metabolism, and endothelial function [55,56]. Moreover, caffeine and chlorogenic acid (CGA) in coffee play a role in insulin homeostasis [57]. Insulin, in turn, causes sodium retention which activates symptomatic nervous system activity and the proliferation of vascular smooth muscle, leading to higher levels of blood pressure [58,59]. Other anti-hypertensive effects of CGA include its anti-inflammatory property [60], inhibitory angiotensin-converting enzyme activity [61], and vasodilation effect through increasing nitric-oxide bioavailability [62].
Our subgroup analyses indicated that the association between coffee and HTN risk differs by countries. Similar to an earlier meta-analysis, we found an in inverse association only in the USA, but not in Europe and Asia in cohort studies. This difference might be explained, at least to some extent, by the amount of coffee consumed. The inverse association between coffee and HTN risk is a non-linear association, and a coffee consumption less than 3 cups/day could not decrease HTN risk [12]. Based on the available evidence, the amount of coffee consumed in European and Asian countries was considerably lower than that of in the USA in 2016 [63]. In addition, the null association in Asian and European countries might be mediated by other variables, such as genetic factors [64], the method used to prepare the coffee, the kind of consumed coffee, and smoking [51,54]. It is also possible that variations in lifestyle and dietary habits in different parts of a continent lead to different association. For instance, Hu et al. [44] failed to find any significant association between coffee and HTN risk in Finland as a North European country, whereas Navarro et al. found an inverse association in Spain as a South European country. However, due to the small number of studies containing such information or located in a specific region, we could not further explore the reason behind this finding.
The characteristics of studies, such as study quality, number of cases, and HTN definition could have affected the association. The results indicated an inverse association between coffee consumption and HTN risk in studies with a larger case number and those which used stage 1 cut-off point for HTN definition. A smaller case number cannot provide enough power to find the expected effect size, which is in concordance with our results as the confidence interval for studies with smaller case number was wider than those with more cases [65].
There was only one study which found a positive direct link between coffee consumption and HTN risk [33]. This study was conducted amongst patients with type 1 diabetes and approximately 50% of their study population consumed antihypertensive medications, which was considered a criterion for having HTN. This might restrict the generalizability of their findings per se.
The main strengths of this meta-analysis are its large population from different countries and ethnicities with a wide age range, a comprehensive literature search to identify relevant articles, and subgroup analysis based on various confounders. Our findings were robust, and no evidence of publication bias was observed. In addition, most cohort studies were long enough to allow investigating incidence of hypertensive cases. We have also investigated a wide range of characteristics of studies which can influence the coffee-HTN association. The first and the main limitation of our study which should be considered for the future studies is the lack of adequate data for determining other plausible heterogeneity sources, such as sodium intake, smoking status, and the type of coffee and its preparing method. For instance, Grosso et al. showed that the association differs by the smoking status of participants. While in the whole population, they reported a null association with a wide confidence interval, in stratified analysis by smoking, they found an inverse association. They found that both non-smoker males and females who drank 3–4 cups coffee/d had lower risk of HTN development, whereas no significant association was found in smokers [37]. Furthermore, it is plausible that in countries which mainly tend to consume instant coffee, coffee consumption exhibits more favorable effects on health status due to its greater antioxidant activities in comparison with brewed coffee [66]. Second, between-studies inconsistency in terms of the adjusted confounders is another limitation which may explain between-studies heterogeneity, and should be considered. Third, estimating the amount of coffee consumption using different approaches, with their own specific measurement errors, may cause misclassification due to the combination of various errors. This, in turn, can affect the accuracy of findings. Fourth, heterogeneity was substantially high in the cross-sectional analysis and it could not be eliminated using subgroup analysis. Therefore, our findings should be interpreted cautiously.
In conclusion, this meta-analysis showed an inverse association between coffee consumption and hypertension incidence, either cross-sectionally or prospectively. However, this association is dependent on the geographical region of the study, participants’ sex, the number of cases, and study quality. Future studies with an appropriate design which consider the effect of other confounders on HTN risk are warranted to confirm this result.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/nu15133060/s1, Supplementary Figure S1: Funnel plots for cohort studies (A) and cross-sectional studies (B).

Author Contributions

Conceptualization, E.A.S. and C.d.O.; methodology, N.M., F.H., P.H., A.M.d.S.R. and E.A.S.; writing—original draft preparation, N.M., F.H., P.H. and A.M.d.S.R.; writing review and editing, C.d.O., E.A.S. and N.S.; supervision, E.A.S. and N.S. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the Economic and Social Research Council [grant number ES/T008822/1].

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Mills, K.T.; Stefanescu, A.; He, J. The global epidemiology of hypertension. Nat. Rev. Nephrol. 2020, 16, 223–237. [Google Scholar] [CrossRef] [PubMed]
  2. Zhou, B.; Carrillo-Larco, R.M.; Danaei, G.; Riley, L.M.; Paciorek, C.J.; Stevens, G.A.; Gregg, E.W.; Bennett, J.E.; Solomon, B.; Singleton, R.K.; et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 2021, 398, 957–980. [Google Scholar] [CrossRef]
  3. Mills, K.T.; Bundy, J.D.; Kelly, T.N.; Reed, J.; Kearney, P.M.; Reynolds, K.; Chen, J.; He, J. Abstract 16828: Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-based Studies From 90 Countries. Circulation 2016, 132, 441–450. [Google Scholar] [CrossRef] [PubMed]
  4. Morze, J.; Danielewicz, A.; Hoffmann, G.; Schwingshackl, L. Diet Quality as Assessed by the Healthy Eating Index, Alternate Healthy Eating Index, Dietary Approaches to Stop Hypertension Score, and Health Outcomes: A Second Update of a Systematic Review and Meta-Analysis of Cohort Studies. J. Acad. Nutr. Diet. 2020, 120, 1998–2031.e15. [Google Scholar] [CrossRef]
  5. Schwingshackl, L.; Schwedhelm, C.; Hoffmann, G.; Knüppel, S.; Iqbal, K.; Andriolo, V.; Bechthold, A.; Schlesinger, S.; Boeing, H. Food Groups and Risk of Hypertension: A Systematic Review and Dose-Response Meta-Analysis of Prospective Studies. Adv. Nutr. 2017, 8, 793–803. [Google Scholar] [CrossRef] [Green Version]
  6. Voskoboinik, A.; Koh, Y.; Kistler, P.M. Cardiovascular effects of caffeinated beverages. Trends Cardiovasc. Med. 2019, 29, 345–350. [Google Scholar] [CrossRef] [PubMed]
  7. Turnbull, D.; Rodricks, J.V.; Mariano, G.F.; Chowdhury, F. Caffeine and cardiovascular health. Regul. Toxicol. Pharmacol. 2017, 89, 165–185. [Google Scholar] [CrossRef]
  8. Rodríguez-Artalejo, F.; López-García, E. Coffee Consumption and Cardiovascular Disease: A Condensed Review of Epi-demiological Evidence and Mechanisms. J. Agric. Food Chem. 2018, 66, 5257–5263. [Google Scholar] [CrossRef] [PubMed]
  9. O’Keefe, J.H.; Bhatti, S.K.; Patil, H.R.; DiNicolantonio, J.J.; Lucan, S.C.; Lavie, C.J. Effects of Habitual Coffee Consumption on Cardiometabolic Disease, Cardiovascular Health, and All-Cause Mortality. J. Am. Coll. Cardiol. 2013, 62, 1043–1051. [Google Scholar] [CrossRef] [Green Version]
  10. Surma, S.; Oparil, S. Coffee and Arterial Hypertension. Curr. Hypertens. Rep. 2021, 23, 38. [Google Scholar] [CrossRef]
  11. Steffen, M.; Kuhle, C.; Hensrud, D.; Erwin, P.J.; Murad, M.H. The effect of coffee consumption on blood pressure and the development of hypertension: A systematic review and meta-analysis. J. Hypertens. 2012, 30, 2245–2254. [Google Scholar] [CrossRef] [PubMed]
  12. D’elia, L.; La Fata, E.; Galletti, F.; Scalfi, L.; Strazzullo, P. Coffee consumption and risk of hypertension: A dose–response meta-analysis of prospective studies. Eur. J. Nutr. 2019, 58, 271–280. [Google Scholar] [CrossRef]
  13. Zhang, Z.; Hu, G.; Caballero, B.; Appel, L.; Chen, L. Habitual coffee consumption and risk of hypertension: A systematic review and meta-analysis of prospective observational studies. Am. J. Clin. Nutr. 2011, 93, 1212–1219. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. De Giuseppe, R.; Di Napoli, I.; Granata, F.; Mottolese, A.; Cena, H. Caffeine and blood pressure: A critical review perspective. Nutr. Res. Rev. 2019, 32, 169–175. [Google Scholar] [CrossRef] [PubMed]
  15. Butt, M.S.; Sultan, M.T. Coffee and its Consumption: Benefits and Risks. Crit. Rev. Food Sci. Nutr. 2011, 51, 363–373. [Google Scholar] [CrossRef]
  16. Chieng, D.; Kistler, P.M. Coffee and tea on cardiovascular disease (CVD) prevention. Trends Cardiovasc. Med. 2022, 32, 399–405. [Google Scholar] [CrossRef]
  17. Peterson, J.; Welch, V.; Losos, M.; Tugwell, P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ott. Ott. Hosp. Res. Inst. 2011, 2, 1–12. [Google Scholar]
  18. Wells, G.; Shea, B.; O’Connell, D.; Peterson, J.; Welch, V.; Losos, M.; Tugwell, P. Newcastle-Ottawa Quality Assessment Scale Cohort Studies; University of Ottawa: Ottawa, ON, Canada, 2014. [Google Scholar]
  19. Zhang, J.; Yu, K.F. What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998, 280, 1690–1691. [Google Scholar] [CrossRef] [Green Version]
  20. DerSimonian, R.; Laird, N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7, 177–188. [Google Scholar] [CrossRef]
  21. Higgins, J.P.T.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327, 557–560. [Google Scholar] [CrossRef] [Green Version]
  22. Flack, J.M.; Adekola, B. Blood pressure and the new ACC/AHA hypertension guidelines. Trends Cardiovasc. Med. 2020, 30, 160–164. [Google Scholar] [CrossRef] [PubMed]
  23. Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 2010, 25, 603–605. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Egger, M.; Smith, G.D.; Schneider, M.; Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315, 629–634. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Egger, M.; Smith, G.D.; Altman, D. Systematic Reviews in Health Care: Meta-Analysis in Context, 2nd ed.; BMJ Publishing Group: London, UK, 2001. [Google Scholar]
  26. Barré, T.; Fontaine, H.; Pol, S.; Ramier, C.; Di Beo, V.; Protopopescu, C.; Marcellin, F.; Bureau, M.; Bourlière, M.; Dorival, C.; et al. Metabolic Disorders in Patients with Chronic Hepatitis B Virus Infection: Coffee as a Panacea? (ANRS CO22 Hepather Cohort). Antioxidants 2022, 11, 379. [Google Scholar] [CrossRef]
  27. Miranda, A.M.; Goulart, A.C.; Benseñor, I.M.; Lotufo, P.A.; Marchioni, D.M. Coffee consumption and risk of hypertension: A prospective analysis in the cohort study. Clin. Nutr. 2021, 40, 542–549. [Google Scholar] [CrossRef]
  28. Micek, A.; Godos, J.; Cernigliaro, A.; Cincione, R.I.; Buscemi, S.; Libra, M.; Galvano, F.; Grosso, G. Polyphenol-Rich and Alcoholic Beverages and Metabolic Status in Adults Living in Sicily, Southern Italy. Foods 2021, 10, 383. [Google Scholar] [CrossRef]
  29. Hou, C.C.; Tantoh, D.M.; Lin, C.C.; Chen, P.H.; Yang, H.J.; Liaw, Y.P. Association between hypertension and coffee drinking based on CYP1A2 rs762551 single nucleotide poly-morphism in Taiwanese. Nutr. Metab. 2021, 18, 78. [Google Scholar] [CrossRef]
  30. Villaverde, P.; Lajous, M.; Macdonald, C.-J.; Fagherazzi, G.; Bonnet, F.; Boutron-Ruault, M.-C. High dietary total antioxidant capacity is associated with a reduced risk of hypertension in French women. Nutr. J. 2019, 18, 31. [Google Scholar] [CrossRef]
  31. Navarro, A.; Martinez-Gonzalez, M.; Gea, A.; Ramallal, R.; Ruiz-Canela, M.; Toledo, E. Coffee consumption and risk of hypertension in the SUN Project. Clin. Nutr. 2019, 38, 389–397. [Google Scholar] [CrossRef]
  32. Gaeini, Z.; Bahadoran, Z.; Mirmiran, P.; Azizi, F. Tea, coffee, caffeine intake and the risk of cardio-metabolic outcomes: Findings from a population with low coffee and high tea consumption. Nutr. Metab. 2019, 16, 28. [Google Scholar] [CrossRef] [Green Version]
  33. Stutz, B.; Ahola, A.; Harjutsalo, V.; Forsblom, C.; Groop, P.-H. Association between habitual coffee consumption and metabolic syndrome in type 1 diabetes. Nutr. Metab. Cardiovasc. Dis. 2018, 28, 470–476. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Micek, A.; Grosso, G.; Polak, M.; Kozakiewicz, K.; Tykarski, A.; Walczak, A.P.; Drygas, W.; Kwaśniewska, M.; Pająk, A. Association between tea and coffee consumption and prevalence of metabolic syndrome in Poland—results from the WOBASZ II study (2013–2014). Int. J. Food Sci. Nutr. 2018, 69, 358–368. [Google Scholar] [CrossRef] [PubMed]
  35. Lee, K.W.; Shin, D. A Healthy Beverage Consumption Pattern Is Inversely Associated with the Risk of Obesity and Metabolic Abnormalities in Korean Adults. J. Med. Food 2018, 21, 935–945. [Google Scholar] [CrossRef] [PubMed]
  36. Chei, C.-L.; Loh, J.K.; Soh, A.; Yuan, J.-M.; Koh, W.-P. Coffee, tea, caffeine, and risk of hypertension: The Singapore Chinese Health Study. Eur. J. Nutr. 2018, 57, 1333–1342. [Google Scholar] [CrossRef]
  37. Grosso, G.; Stepaniak, U.; Polak, M.; Micek, A.; Topor-Madry, R.; Stefler, D.; Szafraniec, K.; Pajak, A. Coffee consumption and risk of hypertension in the Polish arm of the HAPIEE cohort study. Eur. J. Clin. Nutr. 2016, 70, 109–115. [Google Scholar] [CrossRef] [Green Version]
  38. Grosso, G.; Stepaniak, U.; Micek, A.; Topor-Mądry, R.; Pikhart, H.; Szafraniec, K.; Pająk, A. Association of daily coffee and tea consumption and metabolic syndrome: Results from the Polish arm of the HAPIEE study. Eur. J. Nutr. 2015, 54, 1129–1137. [Google Scholar] [CrossRef] [Green Version]
  39. Takami, H.; Nakamoto, M.; Uemura, H.; Katsuura, S.; Yamaguchi, M.; Hiyoshi, M.; Sawachika, F.; Juta, T.; Arisawa, K. Inverse Correlation Between Coffee Consumption and Prevalence of Metabolic Syndrome: Baseline Survey of the Japan Multi-Institutional Collaborative Cohort (J-MICC) Study in Tokushima, Japan. J. Epidemiol. 2013, 23, 12–20. [Google Scholar] [CrossRef] [Green Version]
  40. Guessous, I.; Dobrinas, M.; Kutalik, Z.; Pruijm, M.; Ehret, G.; Maillard, M.; Bergmann, S.; Beckmann, J.S.; Cusi, D.; Rizzi, F.; et al. Caffeine intake and CYP1A2 variants associated with high caffeine intake protect non-smokers from hy-pertension. Hum. Mol. Genet. 2012, 21, 3283–3292. [Google Scholar] [CrossRef] [Green Version]
  41. Uhernik, A.I.; Erceg, M.; Milanović, S.M. Association of BMI and nutritional habits with hypertension in the adult popu-lation of Croatia. Public Health Nutr. 2009, 12, 97–104. [Google Scholar] [CrossRef] [Green Version]
  42. Kokaze, A.; Ishikawa, M.; Matsunaga, N.; Karita, K.; Yoshida, M.; Ohtsu, T.; Shirasawa, T.; Sekii, H.; Ito, T.; Kawamoto, T.; et al. NADH Dehydrogenase Subunit-2 237 Leu/Met Polymorphism Modulates the Effects of Coffee Consumption on the Risk of Hypertension in Middle-Aged Japanese Men. J. Epidemiol. 2009, 19, 231–236. [Google Scholar] [CrossRef] [Green Version]
  43. Uiterwaal, C.S.; Verschuren, W.M.; Bueno-De-Mesquita, H.B.; Ocké, M.; Geleijnse, J.M.; Boshuizen, H.C.; Peeters, P.H.; Feskens, E.J.; Grobbee, D.E. Coffee intake and incidence of hypertension. Am. J. Clin. Nutr. 2007, 85, 718–723. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Hu, G.; Jousilahti, P.; Nissinen, A.; Bidel, S.; Antikainen, R.; Tuomilehto, J. Coffee consumption and the incidence of antihypertensive drug treatment in Finnish men and women. Am. J. Clin. Nutr. 2007, 86, 457–464. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Winkelmayer, W.C.; Stampfer, M.J.; Willett, W.C.; Curhan, G.C. Habitual Caffeine Intake and the Risk of Hypertension in Women. JAMA 2005, 294, 2330–2335. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Klag, M.; Wang, N.; Meoni, L. Coffee intake and risk of hypertension. The Johns Hopkins precursors study. Arch. Intern. Med. 2002, 162, 657–662. [Google Scholar] [CrossRef] [Green Version]
  47. Tan, L.-J.; Jeon, H.J.; Park, S.; Kim, S.-A.; Lim, K.; Chung, S.; Chang, P.-S.; Lee, J.-K.; Kang, D.; Shin, S. Association of Coffee Consumption and Its Types According to Addition of Sugar and Creamer with Metabolic Syndrome Incidence in a Korean Population from the Health Examinees (HEXA) Study. Nutrients 2021, 13, 920. [Google Scholar] [CrossRef]
  48. Nina, R.; Lingling, H.; Qiushuang, L.; Honglin, G.; Liyuan, S.; Yuting, Z. Association of coffee consumption pattern and metabolic syndrome among middle-aged and older adults: A cross-sectional study. Front. Public Health 2023, 11, 1022616. [Google Scholar] [CrossRef]
  49. An, H.-J.; Kim, Y.; Seo, Y.-G. Relationship between Coffee, Tea, and Carbonated Beverages and Cardiovascular Risk Factors. Nutrients 2023, 15, 934. [Google Scholar] [CrossRef]
  50. Rhee, J.J.; Qin, F.; Hedlin, H.K.; Chang, T.I.; Bird, C.E.; Zaslavsky, O.; Manson, J.E.; Stefanick, M.L.; Winkelmayer, W.C. Coffee and caffeine consumption and the risk of hypertension in postmenopausal women. Am. J. Clin. Nutr. 2016, 103, 210–217. [Google Scholar] [CrossRef] [Green Version]
  51. Grosso, G.; Micek, A.; Godos, J.; Pajak, A.; Sciacca, S.; Bes-Rastrollo, M.; Galvano, F.; Martinez-Gonzalez, M.A. Long-Term Coffee Consumption Is Associated with Decreased Incidence of New-Onset Hypertension: A Dose–Response Meta-Analysis. Nutrients 2017, 9, 890. [Google Scholar] [CrossRef] [Green Version]
  52. Xie, C.; Cui, L.; Zhu, J.; Wang, K.; Sun, N.; Sun, C. Coffee consumption and risk of hypertension: A systematic review and dose–response meta-analysis of cohort studies. J. Hum. Hypertens. 2018, 32, 83–93. [Google Scholar] [CrossRef]
  53. Han, M.; Oh, Y.; Myung, S.-K. Coffee Intake and Risk of Hypertension: A Meta-Analysis of Cohort Studies. J. Korean Med. Sci. 2022, 37, e332. [Google Scholar] [CrossRef]
  54. Guessous, I.; Eap, C.B.; Bochud, M. Blood Pressure in Relation to Coffee and Caffeine Consumption. Curr. Hypertens. Rep. 2014, 16, 468. [Google Scholar] [CrossRef] [PubMed]
  55. Emami, M.R.; Safabakhsh, M.; Alizadeh, S.; Asbaghi, O.; Khosroshahi, M.Z. Effect of vitamin E supplementation on blood pressure: A systematic review and meta-analysis. J. Hum. Hypertens. 2019, 33, 499–507. [Google Scholar] [CrossRef] [PubMed]
  56. Zeman, M.; Vecka, M.; Perlík, F.; Staňková, B.; Hromádka, R.; Tvrzická, E.; Širc, J.; Hrib, J.; Žák, A. Pleiotropic effects of niacin: Current possibilities for its clinical use. Acta Pharm. 2016, 66, 449–469. [Google Scholar] [CrossRef] [Green Version]
  57. Santos, R.M.M.; Lima, D.R.A. Coffee consumption, obesity and type 2 diabetes: A mini-review. Eur. J. Nutr. 2016, 55, 1345–1358. [Google Scholar] [CrossRef]
  58. Schwartz, S.M. Smooth muscle proliferation in hypertension. State-of-the-art lecture. Hypertension 1984, 6, I56–I61. [Google Scholar] [CrossRef]
  59. Fisher, J.P.; Paton, J.F.R. The sympathetic nervous system and blood pressure in humans: Implications for hypertension. J. Hum. Hypertens. 2012, 26, 463–475. [Google Scholar] [CrossRef] [Green Version]
  60. Godos, J.; Pluchinotta, F.R.; Marventano, S.; Buscemi, S.; Li Volti, G.; Galvano, F.; Grosso, G. Coffee components and cardiovascular risk: Beneficial and detrimental effects. Int. J. Food Sci. Nutr. 2014, 65, 925–936. [Google Scholar] [CrossRef]
  61. Ardiansyah; Ohsaki, Y.; Shirakawa, H.; Koseki, T.; Komai, M. Novel effects of a single administration of ferulic acid on the regulation of blood pressure and the hepatic lipid metabolic profile in stroke-prone spontaneously hypertensive rats. J. Agric. Food Chem. 2008, 56, 2825–2830. [Google Scholar] [CrossRef]
  62. Suzuki, A.; Kagawa, D.; Fujii, A.; Ochiai, R.; Tokimitsu, I.; Saito, I. Short- and long-term effects of ferulic acid on blood pressure in spontaneously hypertensive rats. Am. J. Hypertens. 2002, 15, 351–357. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  63. Khaledi, M.; Haghighatdoost, F.; Feizi, A.; Aminorroaya, A. The prevalence of comorbid depression in patients with type 2 diabetes: An updated systematic review and meta-analysis on huge number of observational studies. Acta Diabetol. 2019, 56, 631–650. [Google Scholar] [CrossRef] [PubMed]
  64. Palatini, P.; Ceolotto, G.; Ragazzo, F.; Dorigatti, F.; Saladini, F.; Papparella, I.; Mos, L.; Zanata, G.; Santonastaso, M. CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension. J. Hypertens. 2009, 27, 1594–1601. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Kang, M.; Ragan, B.G.; Park, J.-H. Issues in Outcomes Research: An Overview of Randomization Techniques for Clinical Trials. J. Athl. Train. 2008, 43, 215–221. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Brezová, V.; Šlebodová, A.; Staško, A. Coffee as a source of antioxidants: An EPR study. Food Chem. 2009, 114, 859–868. [Google Scholar] [CrossRef]
Nutrients 15 03060 g001 550
Figure 1. The flowchart of study selection.
Figure 1. The flowchart of study selection.
Nutrients 15 03060 g001
Nutrients 15 03060 g002 550
Figure 2. Forest plot of prospective cohort studies investigating the association of coffee with hypertension risk [27,30,31,32,36,37,43,44,45,46,47,50].
Figure 2. Forest plot of prospective cohort studies investigating the association of coffee with hypertension risk [27,30,31,32,36,37,43,44,45,46,47,50].
Nutrients 15 03060 g002
Nutrients 15 03060 g003 550
Figure 3. Forest plot of cross-sectional studies investigating the association of coffee with hypertension risk [26,28,29,33,34,35,38,39,40,41,42,48,49].
Figure 3. Forest plot of cross-sectional studies investigating the association of coffee with hypertension risk [26,28,29,33,34,35,38,39,40,41,42,48,49].
Nutrients 15 03060 g003
Table
Table 1. General characteristics of included cohort studies in the meta-analysis.
Table 1. General characteristics of included cohort studies in the meta-analysis.
First Author (Year)Study Location/SettingSex/Age Range or Mean (Year)Case/TotalDuration Follow-Up (Year)Outcome Assessment/HTN DefinitionCoffee Intake AssessmentType of CoffeeReport of Coffee Intake OR or RR or HR (95% CI)Quality Assessment Adjustments
Klag
(2002) [46]		USAM/26 years281/101733 yearsSelf-report/≥160/≥95 mmHgQuestionnaireCaffeinatedCoffee
>5 vs. 0 cups/day		RR (95% CI)
1.07 (0.67–1.69)		6Parental history of HTN, smoking, alcohol, physical activity, and BMI
Winkelmayer
(2005) [45]		USA/NHS I and IIF/25–55 yearsNHS I: 18,955/53,175
NHS II: 13,468/87,369 		12 years
NHS I: 1990–2002 and NSH II: 1991–2003		Self-reported diagnosis of HTN/≥140/≥90 mmHgFFQCaffeinated and decaffeinatedCaffeinated coffee
≥6 vs. <1 cup/d		Caffeinated:
RR (95% CI)
NHS I:
0.88 (0.80–0.98)
NSH II: 0.91 (0.80–1.04)		6Age, BMI, alcohol, family history of HTN, oral contraceptive use (in Nurses’ Health Study II only), physical activity, and smoking
Hu
(2007) [44]		FinlandM/F/25–64 years2505/24,71013.2 yearsSelf-reported initiation of antihypertensive drug treatment/Incidence of antihypertensive drugFFQ/QuestionnaireNRCoffee ≥8 vs. 0–1 cups/dayHR (95% CI)
1.13 (0.94–1.36) 		7Age, sex, study year, education, physical activity, smoking, alcohol, tea, frequency of vegetable, fruit, sausage, and bread consumption, BMI, history of diabetes, total cholesterol and baseline SBP
Uiterwall
(2007) [43]		USAM/F/Men: 40.7 ± 10.0
Women: 40.1 ± 10.3		956/518911 yearsMeasurement/≥140/≥90 mmHgQuestionnaireRegular, decaffeinated or otherAll type of coffees:
>6 vs. 0 cups/day		Coffee:
OR (95% CI)
All: 0.83 (0.65–1.07)
Men:
1.03 (0.72–1.46)
Women:
0.67 (0.46–0.98)		8Age, sex, BMI smoking, alcohol, tea, education level, occupational status, and total energy intake.
Grosso (2016) [37] Poland/HAPIEE projectM/F/45–69 years1735/27255 yearsMeasurement/>139/>89 mmHgFFQNR but mostly caffeinatedCoffee
>4 vs. <1 cups/day		OR (95% CI)
All: 1.58 (0.85–3.64)
Men:
2.42 (0.66–8.91)
Women:
1.09 (0.36–3.33)		7Age, sex, education, occupation, BMI, alcohol, smoking, physical
activity, history of CVD, diabetes at baseline, cholesterol therapy at baseline, total energy intake, vitamin supplement use, oral contraceptives use, sodium and potassium intakes
Rhee
(2016) [50]		USA/The Women’s Health Initiative Observational StudyF/50–79 years5566/29,985-Measurement/≥140/≥90 mmHgFFQCaffeinated and decaffainated Caffeinated and decaffeinated: ≥4 vs. 0 cups/dayCaffeinated:
HR (95% CI)
0.99 (0.90–1.08)		7Age, baseline blood pressure, BMI, physical activity, hormone replacement therapy, alcohol consumption, smoking, total caloric intake, and
intakes of sodium, magnesium, calcium, potassium, and phosphorus as time-varying covariates.
Chei (2018) [36]Singapore/The Singapore Chinese Health StudyM/F/45–74 years13,658/38,5929.5 yearsSelf-report/-FFQCaffeinatedCategorized
Coffee ≥3 vs. 1 cups/day		HR (95% CI)
0.93 (0.86–1.00)		7Age at recruitment (years), year of recruitment, sex, dialect group, BMI, education level, smoking, physical activity, sleep duration, and dietary intake of sodium, vegetables, fruits, and dairy products
Gaeini (2019) [32] Iran/TLGSM/F/≥19 years291/18786 yearsMeasuring/≥140/≥90 mmHg or self-reported usage of blood pressure lowering medicationsFFQNRCoffee
Drinkers vs. non-drinkers		HR (95% CI)
0.83 (0.63–1.10)		7Sex, age, BMI, Triglyceride to HDL-C ratio, total energy intake
Navarro (2019) [31]Spain/The SUN ProjectM/F/35.7 ± 10.41750/13,3699.1 yearsQuestionnaires/≥140/≥90 mmHgFFQRegular and decaffeinated coffeeCaffeinated and decaffeinated coffee:
≥2 vs. 0 cups/day		HR (95% CI)
0.86 (0.75–0.99)		6Age, BMI, alcohol, smoking and package-years of smoking, family history of HTN, sodium intake, whole and low fat dairy products consumption, sugar-sweetened beverages, non-sugared carbonated beverages, physical activity, adherence to Mediterranean diet, kind of personality), time spent watching TV and fried and fast-food consumption
Villaverde (2019) [30]France/E3NF/51.6 ± 6.29350/40,56712.7 yearsQuestionnaire/-Diet history questionnaireNRTAC (mmol/day)
Quantile 5 vs. quantile 1		HR (95% CI)
0.91 (0.80; 1.04)		7Age as the time scale, energy without alcohol, diabetes, treated hypercholesterolemia, education, family history of HTN, smoking, physical activity, BMI, Na, K, Mg, AGPIw3, alcohol
Miranda (2021) [27]Brazil/ELSAM/F/35–74 years1285/87803.9 yearsMeasuring/≥140/≥90 mmHg And/or taking anti-hypertensive medicationsFFQCaffeinated coffeeCoffee >3 vs. ≤1 cups/dayRR (95% CI)
0.85 (0.70–1.04)		6Age, sex, race/skin color, educational attainment, household per capita income, BMI, physical activity level, smoking, alcohol, dietary intake of fruits, vegetables, sodium, potassium, saturated fat, added sugars, total energy intake, supplement use, fasting glucose, total cholesterol, and triglycerides
Tan (2021) [47]Japan/HEXAM/F/≥40 years38975Measurement/≥130/≥80 mmHg FFQNRCoffee
>3 vs. 0 cups/day		RR (95% CI)
0.85 (0.64, 1.15)		7Age, BMI, energy intake, educational level, current drinking status, current smoking status, and physical activity
Table
Table 2. General characteristics of included cross-sectional studies in the meta-analysis.
Table 2. General characteristics of included cross-sectional studies in the meta-analysis.
First Author (year)Study Location/SettingAge Range/Mean Age (year)Case/TotalOutcome AssessmentCoffee Intake AssessmentType of CoffeeReport of Coffee Intake OR or RR or HR (95% CI)Quality Assessment Adjustments
Kokaze
(2009) [42]		JapanM/53.8 ± 7.8 years398Measurement/≥140/≥90 mmHgQuestionnaireNRCoffee > 4 vs. ≤1 cups/dayOR
≤1: 1
2–3: 0.56 (0.34–1.01)
>4: 0.58 (0.23–1.45)		6Age, BMI, alcohol, smoking, serum total cholesterol level, serum HDL level, fasting plasma glucose level, serum uric acid level, and green tea.
Uhernik
(2008) [41]		CroatiaM/F/>18 years10,766Measurement/≥140/≥90 mmHgQuestionnaireNRCoffee
≥3 vs. 0 cups/day		OR (95% CI)
All:
0.6 (0.5–0.8) Men:
0.5 (0.3–0.7)
Women:
1.1 (0.8–1.6)		6-
Guessous
(2012) [40]		Switzerland/The CoLaus studyM/35–75 years6127/
Non-smokers: 4480 Smokers: 1647		Measurement/≥140/≥90 mmHgQuestionnaireNRCoffee
>6 vs. 0 cups/day		OR (95% CI)
Non-smokers
0.59 (0.34–1.02)
Smokers:
0.96 (0.38–2.42)		8Age, sex, BMI, contraceptive use, total cholesterol, triglycerides, diabetes, alcohol, CKD-EPI, CYP1A2 variants, menopause and p-value for interaction test.
Takami (2013) [39]Japan/the Japan Multi-Institutional Collaborative Cohort (J-MICC) Study M/F/35–70 years172/554Measurement/≥130/≥85 mmHgQuestionnaireNRRarely
<2, 3–4 and 5–6 cups/week
1–2, 3–4 and ≥5 cups/day		OR (95% CI)
<1.5: 1
≥1.5 and <3: 0.89 (0.55–1.45)
≥3: 0.82 (0.49–1.36)		8Age, sex, total energy intake, physical activity, smoking and drinking habits
Grosso (2015) [38]Poland/arm of the HAPPIE studyM/F/45–69 years8821Measurement/≥130/≥85 mmHgFFQNRCoffee
≥2 vs. <1 cups/day		OR (95% CI)
All: 0.78 (0.69–0.88)
Men:
0.88 (0.74–1.06)
Women:
0.78 (0.65–0.95)		8Sex, age, educational level, occupational level, physical activity, smoking, alcohol, total energy intake, and tea consumption
Lee (2018) [35]KoreaM/F/19–64 years15,713Measurement/≥130/≥85 mmHg24-h dietary recallNRCoffee pattern
T3 vs. T1		OR (95% CI)
0.97 (0.87–1.09)		7Sex, age, education level, income, smoking, physical activity, BMI (except for obesity and abdominal obesity), day of recalled intake; total daily energy intake.
Micek (2018) [34]PolandM/F/≥20 years5164Measurement/≥130/≥85 mmHg or treatment of previously diagnosed HTN24-h dietary recallNRCoffee >400 vs. 0 g/dayOR (95% CI)
0.74 (0.60–0.92)		8Sex, age, educational and occupational status, physical activity, smoking, alcohol, total energy intake, and tea consumption
Stutz (2018) [33]Finland/the Finish Diabetic Nephropathy Study M/F/46.7 ± 0.41040Measurement/≥130/≥85 mmHg or use of hypertensive medicationFFQNRCoffee ≥5 vs. <1 cup/d OR (95% CI)
2.19 (1.08–4.44)		8Age, sex, energy intake, alcohol, physical activity, and smoking
Hou (2021) [29]Taiwan/Biobank databaseM/F/30–70 years3411/19,133Questionnaire/-Self-reportsNRCoffee drinkers (at least thrice per week) vs. non-drinkers (habitually drank coffee less than three times per week)OR (95% CI)
0.877(0.807–0.954)		5-
Micek (2021) [28]Italy/MEALM/F/≥18 years2044Measurement/≥140/≥90 mmHg Or medical
history of taking anti-hypertensive medications		FFQNRCategorized
T3 (67.6 ± 39.5 mL/d) vs. T1 (47.6 ± 51.9 mL/d)		OR (95% CI)
0.64
(0.48–0.86)		9Total energy intake, all beverages investigated, age, sex, educational status, smoking, physical activity level, adherence to the Mediterranean diet
Barré (2022) [26]France M/F/43 ± 14.814590Self-report/Self-report or receiving treatmentQuestionnaireNRCoffee
≥3 vs. 0 cups/day		OR (95% CI)
0.66 (0.51–0.85)		6Age, sex, place of birth, living in a couple, tea, cannabis use, tobacco, alcohol, living in poverty
Hye-Ji An (2023) [49]Korea/Korea National Health and Nutrition Examination SurveysM/F/Men: 41.34 ± 0.15
Women: 42.39 ± 0.15		42,613 (17,311 men and 25,302 women)Measurement/≥130/≥85 mmHg or medications FFQNRCoffee ≥1 time/d vs. <1 time/wkOR (95% CI)
Men: 0.66 (0.52, 0.84)
Women: 0.92 (0.77, 1.11)		9Age, the frequency of intake of tea, and carbonated beverages, daily nutritional intake (total and fat), income, education, smoking, alcohol drinking, walking, BMI, and menopausal status (only in women)
Nina R (2023) [48]ChinaM/F/≥40 years1719 (800 men, 919 women)Measurement/≥130/≥85 mmHg2-day, 24-h recallNR>1 serving/day vs. non-coffee drinkersOR (95% CI)
Men: 0.88 (0.72, 1.08)
Women: 0.79 (0.60, 1.04)		9BMI, education level, alcohol status, Physical activity
Table
Table 3. Subgroup analyses for the association between coffee intake and hypertension risk.
Table 3. Subgroup analyses for the association between coffee intake and hypertension risk.
Number of EffectsEffect Size95% Confidence IntervalI2 (%)p-for between Subgroup
Heterogeneity
Cohorts
Region 0.924
US60.920.87, 0.970.7
Europe40.970.83, 1.1360.5
Asia30.940.83, 1.0725.0
Age 0.444
<50 years70.910.84, 0.9923.8
>50 years60.940.89, 1.0028.5
Sample size 0.244
<median (n = 20,000)70.890.81, 0.9912.6
>median (n = 20,000)60.940.84, 0.9930.8
Number of cases 0.967
<300080.940.84, 1.0643.0
>300050.930.89, 0.970.0
Follow-up duration 0.506
<10 years60.910.84, 0.9922.3
>10 years70.940.88, 1.0030.0
Sex 0.833
Men11.070.67, 1.70-
Women40.930.88, 0.984.9
Both80.930.85, 1.0241.3
HTN stage 0.149
≥130 mmHg for SBP and/or 80 mmHg for DBP11.190.85, 1.65-
≥140 mmHg for SBP and/or 90 mmHg for DBP120.920.88, 0.9717.7
Study quality 0.056
Low50.880.83, 0.940.0
High80.960.90, 1.0334.2
Cross-sectionals
Region <0.0001
Europe80.720.62, 0.8454.6
Asia80.870.81, 0.9533.3
Sample size 0.078
<median (n = 8000)80.780.66, 0.9148.5
>median (n = 8000)80.810.72, 0.9070.9
Sample size 0.733
<median (n = 3000)70.840.67, 1.0447.3
>median (n = 3000)90.780.70, 0.8772.6
Sex 0.423
Men40.750.61, 0.9331.4
Women20.880.75, 1.020.0
Both100.790.70, 0.8973.4
HTN stage 0.154
≥130 mmHg for SBP and/or 80 mmHg for DBP50.880.73, 1.0675.2
≥140 mmHg for SBP and/or 90 mmHg for DBP110.760.68, 0.8555.7
Study quality 0.637
Low40.710.55, 0.9177.0
High120.820.73, 0.9159.9
HTN: hypertension.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Haghighatdoost, F.; Hajihashemi, P.; de Sousa Romeiro, A.M.; Mohammadifard, N.; Sarrafzadegan, N.; de Oliveira, C.; Silveira, E.A. Coffee Consumption and Risk of Hypertension in Adults: Systematic Review and Meta-Analysis. Nutrients 2023, 15, 3060. https://doi.org/10.3390/nu15133060

AMA Style

Haghighatdoost F, Hajihashemi P, de Sousa Romeiro AM, Mohammadifard N, Sarrafzadegan N, de Oliveira C, Silveira EA. Coffee Consumption and Risk of Hypertension in Adults: Systematic Review and Meta-Analysis. Nutrients. 2023; 15(13):3060. https://doi.org/10.3390/nu15133060

Chicago/Turabian Style

Haghighatdoost, Fahimeh, Parisa Hajihashemi, Amanda Maria de Sousa Romeiro, Noushin Mohammadifard, Nizal Sarrafzadegan, Cesar de Oliveira, and Erika Aparecida Silveira. 2023. "Coffee Consumption and Risk of Hypertension in Adults: Systematic Review and Meta-Analysis" Nutrients 15, no. 13: 3060. https://doi.org/10.3390/nu15133060

APA Style

Haghighatdoost, F., Hajihashemi, P., de Sousa Romeiro, A. M., Mohammadifard, N., Sarrafzadegan, N., de Oliveira, C., & Silveira, E. A. (2023). Coffee Consumption and Risk of Hypertension in Adults: Systematic Review and Meta-Analysis. Nutrients, 15(13), 3060. https://doi.org/10.3390/nu15133060

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop